Phase II trial in Japan of sequential administration of weekly paclitaxel followed by FEC as neoadjuvant chemotherapy for locally advanced breast cancer [KBCSG0206 trial: Kinki breast cancer study group (KBCSG)]

Oncology

Volumn 78, Issue 5-6, 2010, Pages 302-308

  Taguchi, Tetsuya ^a   Masuda, Norikazu ^b   Nakayama, Takahiro ^c   Motomura, Kazuyoshi ^d   Tsukamoto, Fumine ^e   Shimazu, Kenzo ^e   Nomura, Takashi ^f   Morimoto, Takashi ^f   Yamamoto, Hiroshi ^g   Wakita, Kazuyuki ^h   Nakano, Yoshiaki ⁱ   Yoneda, Kohri ^j   Inaji, Hideo ^d   Takatsuka, Yuichi ^k   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c SAKAI MUNICIPAL HOSPITAL   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^e OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^f Yao Municipal Hospital   (Japan)

^g Minoh City Hospital   (Japan)

^h YODOGAWA CHRISTIAN HOSPITAL   (Japan)

ⁱ OSAKA POLICE HOSPITAL   (Japan)

^j Suita Municipal Hospital   (Japan)

^k KANSAI ROSAI HOSPITAL   (Japan)

more..

Author keywords

5 Fluorouracil; Breast cancer; Cyclophosphamide; Epirubicin; Neoadjuvant chemotherapy; Paclitaxel

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; RANITIDINE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER STAGING; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TUMOR VOLUME; VOMITING; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; JAPAN; MIDDLE AGED; MORTALITY; PATHOLOGY; POSTMENOPAUSE; PREMENOPAUSE; SURVIVAL; TOXICITY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; JAPAN; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; POSTMENOPAUSE; PREMENOPAUSE; SURVIVAL ANALYSIS;

EID: 77954202187     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318169     Document Type: Article

References (21)

1. Ajiki W: Cancer statistics; in Japanese Society of Medical Oncology (eds): Clinical Oncology Update-Essential for Medical Oncologists. Tokyo, Nankodo, 2006, pp 105-109.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
3. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30: 96-102.
4. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19: 4224-4237.
5. Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH: Primary systemic therapy of breast cancer. Oncologist 2006; 11: 574-589.
6. Kim SJ, Taguchi T, Shimazu K, Tanji Y, Tamaki Y, Noguchi S: Good response to paclitaxel predicts high rates of pathologic complete response for breast cancer patients treated preoperatively with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide. Oncology 2009; 77: 134-139.
7. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005; 23: 5983-5992.
8. Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, Zambetti M, Valagussa P, Bonadonna G, ECTO Study Group: European Cooperative Trial in Operable Breast Cancer (ECTO): improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF) (abstract 513). Proc Am Soc Clin Oncol 2005; 23: 7s.
9. Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer. Breast Cancer 2005; 12:S15.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
11. Japanese Breast Cancer Society: Japan Breast Cancer Society EBM Guideline for Surgical Therapy. Tokyo, Kanehara, 2005, pp 50-51.
12. Diéras V, Fumoleau P, Romieu G, Tubiana- Hulin M, Namer M, Mauriac L, Guastalla JP, Pujade-Lauraine E, Kerbrat P, Maillart P, Pénault- Llorca F, Buyse M, Pouillart P: Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004; 22: 4958-4965.
13. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019-2027.
14. Untch M, Konecny G, Ditsch N, Sorokina Y, Moebus V, Muck B, Kuhn W, Bastert G, Werner C, Thomssen C, Wallwiener D, Albert U, Bothmann G, Kreienberg R, Lück HJ: Dosedense sequential epirubicinpaclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study. J Clin Oncol 2002; 21: 133a.
15. von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe D, Jackisch C, du Bois A, Kaufmann M: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23: 2676-2685.
16. Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y, Japan Breast Cancer Research Group (JBCRG): Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 2008; 110: 531-539.
17. Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW: Weekly paclitaxel plus carboplatin is an effective nonanthracycline- containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol DOI: 10.1093/annonc/mdq041.
18. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-1671.
19. Taguchi T, Aihara T, Takatsuka Y, Shin E, Motomura K, Inaji H, Noguchi S, Kinki Breast Cancer Study Group: Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan. Breast J 2004; 10: 509-513.
20. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S: Taxanebased combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008; 26: 44-53.
21. Taghian AG, Abi-Raad R, Assaad SI, Casty A, Ancukiewicz A, Yeh E, Molokhia P, Attia K, Sullivan T, Kuter I, Boucher Y, Powell SN: Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 2005; 23: 1951-1961.